Twentyeight-Seven Therapeutics focuses on developing innovative small-molecule therapeutics aimed at addressing dysregulated nucleic acid processes, which are critical for maintaining cellular homeostasis. The company emphasizes the importance of nucleic acid (RNA and DNA) processing and signaling in regulating various cellular functions, including metabolism and responses to external stimuli. Their therapeutic approach targets specific enzymes involved in nucleic acid regulation, particularly in the context of serious diseases such as cancer and autoimmune disorders. By understanding the dysregulation of these processes, Twentyeight-Seven aims to create therapies that can restore balance and provide clinical benefits to patients.

The company has developed a unique toolbox that facilitates the rapid generation of small-molecule inhibitors targeting nucleic acid processing and sensing enzymes. This toolbox includes validated chemical and biological reagents, a suite of biochemical and cellular assays, and a curated chemical motif library. Twentyeight-Seven's pipeline features several promising programs, including inhibitors for CLK enzymes associated with aberrant RNA splicing in cancers, dual inhibitors for TUT4 and TUT7 that regulate RNA homeostasis, and inhibitors targeting cGAS, which plays a role in immune responses and cancer. Additionally, the company is advancing inhibitors for PAPD5 and PAPD7, which are involved in RNA stabilization and have implications for diseases like hepatitis B and dyskeratosis congenita.

United States

Our Therapies Restore Balance. We are explorers leading the revolution in RNA drug discovery to develop an entirely new class of therapies. We are identifying the chemical motifs to potently and selectively modulate RNA regulatory networks to treat the most challenging diseases.

Twentyeight-Seven Therapeutics

Company Details